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Abstract 
Salmonella typhimurium, that cause typhoid fever in mice was used as a model to study typhoid fever in humans. This study is 
aimed to determine the immunogenicity of recombinant protein of  Fim-C-S. typhimurium and specificity of antibody anti-
recombinant protein of Fim-C-S. typhimurium in ddY mice. The immunogenicity studies by ELISA indicated that recombinant 
protein of Fim-C-S. typhimurium evokes strong immune response in ddY mice, particularly in experiment group. The specificity 
evaluated by Western Immunobloting technique indicated that the antibody anti-recombinant protein of Fim-C-S. typhimurium 
can detect the 31 kDa of recombinant protein of Fim-C-S. typhimurium as an antigen. This data reported that recombinant protein 
of Fim-C-S. typhimurium is immunogenic and the antibody anti-recombinant protein of Fim-C-S. typhimurium is specific. The 
results of this study can be used as a model to develop recombinant vaccine candidate against typhoid. 
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1. Introduction 
Typhoid fever, caused by Salmonella typhi (S. typhi) bacteria, is a major cause of illness and death, particularly 
among children, in developing countries. By the year 2000, it is estimated 22 million cases of typhoid fever and 
200.000 deaths occurring worldwide3,4,20. However, to study the pathogenesis of S. typhi in human is restricted. 
Thus, the urgency to find a pathogen with similar symptoms should be carried out. Salmonella typhimurium (S.
typhimurium), that cause typhoid fever in mice and has similar symptoms to typhoid fever in human, are used as a 
model.  
Salmonella typhimurium are pathogenic, Gram negative, facultative anaerobic bacilli which have flagels and 
fimbriae and live in human and animal intestinal tracks. The organisms stimulate different effects in different host 
cells. Those cause gastroenteritis in humans, while also typhoid fever in mice. Therefore, S. typhimurium in infected 
mice are used as a model to study the pathogenesis of S. typhi in humans17,21. Typhoid fever is overcome by 
vaccines. Two available vaccines against typhoid, Ty21a (oral vaccine) and Vi CPS (injection vaccine), are 
produced from attenuated strains of S. typhi. However, those vaccines provide moderate protection against typhoid, 
especially in hyper-endemic areas5,8. In Indonesia, effectivity of protection against typhoid is 33%-53% within three 
years lower than other countries21. Therefore, it has stirred an urgency to develop better and efficient typhoid 
vaccines. 
Recombinant protein vaccine is one of the alternatives against typhoid. There are advantages of recombinant 
protein vaccine, such as higher protection for patients, higher purity, more specific, and allowing the production of 
large quantities14,21. The recombinant subunit approaches are being used for the development of new vaccines and 
improvement of already existing vaccines2. Many recombinant vaccines are now being tested in preclinical and 
clinical trials, and some recombinant vaccines are already on the market. Some recombinant vaccine showed at 
Table.1. 
    Table 1. Selected examples of recombinant vaccines currently approved in the US or EU 
Vaccine Description Application Company Approved 
Recombivax rHBsAg produced in S. cerevisiae Hepatitis B prevention Merck 1986 (US) 
Comvax Combination vaccine, containing 
rHBsAg produced in S. cerevisiae 
as one component 
Vaccination of infants against H.
influenzae type B and hepatitis B 
Merck 1996 (US) 
Tritanrix-HB Combination vaccine, containing 
rHBsAg produced in S. cerevisiae 
as one component 
Vaccination against hepatitis B, diphteria, 
tetanus, and pertussis 
SmithKline 
Beecham 
1996 (EU) 
Twinrix, adult 
and pediatric 
forms 
Combination vaccine, containing 
rHBsAg produced in S. cerevisiae 
as one component 
Immunization against hepatitis A and B SmithKline 
Beecham 
1996 (EU) 
(adult)  
1997 (EU) 
(pediatric) 
Primavax Combination vaccine, containing 
rHBsAg produced in S. cerevisiae 
as one component 
Immunization against diphteria, tetanus, 
and hepatitis B 
Pasteur 
Merieux 
MSD 
1998 (EU) 
Procomvax Combination vaccine, containing 
rHBsAg produced in S. cerevisiae 
as one component 
Immunization against H. influenzae type B 
and hepatitis B 
Pasteur 
Merieux 
MSD 
1999 (EU) 
Lymerix rOspA, a surface lipoprotein of B.
burgdorferi, produced in E. coli 
Lyme disease vaccine SmithKline 
Beecham 
1998 (US) 
 
 
The previous research in 2007-2009, we found thirteen potential S. typhi protein, one of them is Fim-C S. typhi, 
using 2D and MALDI TOFF17. In parallel we also study Fim-C S. typhimurium protein as a model. The Fim-C S. 
typhimurium protein as well known outer membrane protein. References analysis indicated that the outer membrane 
proteins of Salmonella have strong immunogenic potential, this characteristic is supporting for development of 
vaccine. The use of recombinant proteins allows the targeting of immune responses focused against few protective 
antigens was studied by Nascimento and Leite [2012]. There are a variety of expression systems with different 
advantages for recombinant protein, such as allowing the production of large quantities of proteins depending on the 
required characteristics, a high purity, specific and easy to handling11. In parallel research, we have been developing 
of recombinant protein of Fim-C-S. typhi as vaccine candidate against typhoid13. Earlier study carried out in our 
 Muktiningsih Nurjayadi et al. /  Procedia Chemistry  18 ( 2016 )  237 – 245 239
laboratory, we have done isolated, cloned, expressed of fim- C- S. typhimurium gene to be recombinant protein of 
fim- C- S. typhimurium, and purified and characterize of recombinant protein of Fim- C- S. typhimurium1,6,17,18,19. 
This study is aimed to determine the immunogenicity of recombinant protein of Fim C S. typhimurium   and 
specificity of anti recombinant protein of Fim-C-S. typhimurium antibody in ddY mice. The research is very 
important as model/basic on developing recombinant typhoid vaccine for human.  
2. Methods 
2.1. Antigen 
Antigen used in this experiment is recombinant protein Fim-C-S. typhimurium in the form inclusion bodies. 
Antigen of Fim-C-S. typhimurium was produced in the previous research using recombinant DNA 
technology1,5,16,17,18. The procedure for production of recombinant protein  of Fim-C-S. typhimurium as follow: (1) 
isolation of  the genome S. typhimurium LT2 by Wizard kit28, (2) amplification of fim-C-S. typhimurium gene 0.7 kb 
size by PCR method (3) cloning gene of fim-C-S. typhimurium 0.7 kb on vector cloning pGMTeasy kit22, which 
constructed recombinant plasmid pGEM-fim-C-S. typhimurum, (4) subcloning gene fim-C-S. typhimurium from 
plasmid recombinant pGEM-fim-C-S. typhimurum  to expression vector pET30A [pET system, Invitogen, 2012] to 
produced plasmid recombinant pET30A- fim-C-S. typhimurum, (5) Expression of recombinant protein of Fim-C-S. 
typhimurum, (6) isolation and purification of recombinant protein of Fim-C-S. typhimurum in inclusion bodies form 
by Hispur kit26. 
Preparation of antigen for imunization as follow as:  the amount of 20-60 Pg recombinant protein Fim-C-S.
typhimurium in inclusion bodies form resulted on the purification disolved with buffer PBS 1x on  Eppendorf 1,5 
mL the total volume was 100-500 PL. Addition  with  Freund’s complete adjuvant (FCA) or  Freund’s incomplete 
adjuvant (FIA) with equal comparation 1:1. Homogenation by vortexing up to the white color appear16. 
2.2. Animal Tested 
Production of antibody anti recombinant protein of Fim-C- S. typhimurium was conducted in ddY strains, 6-8 
weeks old, 17-24 gr male mice. Antibody of anti recombinant protein of Fim-C-S. typhimurium was obtained from 
36 mice that have been categorized into two major groups, experiment group and control group. Each of the 
experiment groups were divided into two sub groups, the group that was immunized by mixed Fim-C S.
typhimurium recombinant protein and Freund complete/incomplete Adjuvant (KP-1) and the  group that was 
immunized only by Fim-C protein dilution in PBS 1x (KP-2). The control groups divided into two sub groups, the 
first group that was immunized by Freund Complete/Incomplete Adjuvant (KS-1) and the other group that was 
immunized by Phosphate Buffer Saline or PBS 1x (KS-2). Each of the groups consisted of 8 mice. Four other mice 
were treated as control in each group. They were categorized into normal group (KN), without immunized11,16. 
2.3. Immunization 
Immunization was conducted as many as four times in day 1, day 9, day 17, and day 25. Each immunization was 
performed in 1-2 injections using 20 ȝg (dose 1), 40 ȝg (dose 2) and 60 ȝg (dose 3 and 4) on the dorsal near head for 
experiment groups11. 
2.4. Test Bleeds 
Test bleeds were done from mice’s eyes sinus orbitalis. Pre-immune serum was taken before the treatment began 
(day 0). Continuously, the test bleed was taken on day 8 (test bleed 1), day 16 (test bleed 2), day 24 (test bleed 3), 
and day 32 (test bleed 4). 500 PL bloods from eyes sinus orbitalis was incubated at 37oC for 1 hour and was 
centrifuged at 5000 g for 10 minutes at 4oC. The serum was removed from the cell pallet and inserted to sterile 
Eppendorf tube. The serum then was frozen at -20oC. The yield was approximately 100-200 PL11. 
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2.5. Enzyme Linked Immuno Sorbent Assay (ELISA)
As much as 100 ng and 300 ng of Fim-C S. typhimurium recombinant protein were used as antigen in ELISA. 
Antibody of anti recombinant protein of Fim-C-S. typhimurium in ELISA was diluted 100 times. Amount of 50 μL 
antigen diluted in PBS was incubated in each well micro titer plate at room temperature. Each well was washed 
three times with PBS contained by 1 mM MgCl2 and 0.05% (v/v) Tween-20. As much as 150 μL 5% blotto (5 g 
skimmed milk in 100 mL PBS) was added in each well, and then micro titer plate was incubated at 37°C for one 
hour. Micro titer plate was washed three times with PBS. The 50 μL mice serum from the fourth test bleeds with 
1000 times dilution concentration was added in each well and incubated at 37°C for one hour. The plate was washed 
three times with PBS. The 50 μL labeled secondary antibody (anti IgG-mice-HRP diluted 5000 times)17 was added 
to plate, and then incubated at 37°C for one and a half hour. Micro titer plate well was washed with washing buffer 
for three times. 50 μL substrate solution TMB (3,3’,5,5’-tetramethylbenzidine, Thermo Scientific) 25,29 was added in 
each well and incubated at at 37°C for one hour. The color formation reaction was stopped by adding 50 μL H2SO4. 
After the incubation, it was measured the absorbance value by ELISA-Reader in 450 nm wave length. The result 
was the absorbance value in each well8,11,16. 
2.6. Specificity Test by Western Immunobloting. 
Serological test antibody of anti recombinant protein of Fim-C-S. typhimurium against antigen of recombinant 
protein Fim-C-S. typhimurium was performed by Western immunoblotting method. In the previous research 
characterization of 31 kDa Fim-C S. typhimurium protein was performed6. The result of protein separating by SDS-
PAGE gel was transferred to nitrocellulose membrane using Western immunoblotting apparatus. Protein transfer 
process was taken at 4°C 200 V in 2-3 hours. Membrane was blocked with skimmed milk to avoid interaction 
between primary and secondary antibody. Primary antibody added to membrane was the serum from the fourth test 
bleed with 1000 times dilution concentration8,11. 
3. Results and discussion  
3.1. Immunogenicity Test of Recombinant Protein of Fim-C-S. typhimurium as Antigen 
Immunogenicity is the ability of a particular substance, such as an antigen or epitope, to provoke an immune 
response in the body of a human or animal. In other words, immunogenicity is the ability to induce a humoral and/or 
cell mediated immune response9,11. To evaluate the immunogenicity of recombinant protein of Fim-C S.
typhimurium, the pure recombinant protein described above was prepared for immunization experiment. The ddY 
mice were immunized with the antigen formulated with Freund’s complete/incomplete adjuvants. Immunization of 
mice with increasing protein doses (20 ȝg, 40 ȝg, 60 ȝg, and 60 ȝg) indicated that a 60 ȝg dose gave the highest 
anti-Fim-C-S. typhimurium antibody response (Table 2 and Fig. 2).  
To compare the immunogenicity of recombinant protein of Fim-C S. typhimurium, in this research the ddY mice 
divided in two groups, they are experiment and control group as describe above. The antibody response showed with 
increasing absorbance value from ELISA process. As we known the increasing absorbance value shows interaction 
between recombinant protein of Fim-C S. typhimurium as antigen and antibody anti recombinant protein of Fim-C-
S. typhimurium. Those interaction showed with the link of the antigen, primary antibody (anti recombinant protein 
of Fim-C-S. typhimurium antibody) and secondary antibody anti-mice conjugated with Horse Radish Peroxidase 
(HRP) enzyme. Therefore HRP bonded on secondary antibody will oxidize the substrate TMB (3,3’,5,5’-
Tetramethylbenzidine) became 3,3',5,5'-tetramethylbenzidine diimine.
The resulting diimine causes the solution to take on a blue color, and this color change can be observed on a 
spectrophotometer at a wavelength of 650 nm. The reaction can be stopped by addition of acid or another stopper 
reagent. Using sulfuric acid turns TMB to be yellow. The color may be read at 450 nm and a higher antibody titre 
produced the thicker colour appear. The oxidation reaction of changing 3,3’,5,5’-tetramethylbenzidine became 
3,3',5,5'-tetramethylbenzidinediimine showed at Fig.124,29. 
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Fig. 1. Oxidation reaction of 3,3’,5,5’-tetramethylbenzidine became 3,3',5,5'-tetramethylbenzidine diimine. The TMB substrate can act as a 
hydrogen donor for the reduction of hydrogen peroxide to water by peroxidase enzymes such as horseradish peroxidase [Wikipedia.org; Sigma 
Aldrich Catalogue] 
 
Antigen concentrations in ELISA test were 100 ng and 300 ng. In the experiment group, each of test bleed 
produced a higher absorbance in 300 ng antigen concentration. The higher antigen concentration bound higher 
amount of antibody. Antigen-antibody interaction, or antigen-antibody reaction, it is a specific chemical interaction 
between antibodies produced by B cells of the white blood cells and antigens during immune reaction. It is the 
fundamental reaction in the body by which the body is protected from complex foreign molecules, such as 
pathogens and their chemical toxins. In the blood, the antigens are specifically and with high affinity bound by 
antibodies to form an antigen-antibody complex. The immune complex is then transported to cellular systems where 
it can be destroyed or deactivated18. 
Table 2 and Fig. 2 show the amount of antibody titer in each test bleed from experiment and control groups. 
Antibody titer in experiment group 1 (KP-1) and experiment group 2 (KP-2) increased in every test bleeds, that 
showed the increasing antibody response against the antigen. Antibody titer of control group 1 (KS-1, immunized by 
adjuvant) and control group 2 (KS-2, immunized by PBS) continuously did not perform the increasing antibody 
response. Those results showed that Fim-C S. typhimurium protein has satisfying as immunogenicity. 
  Table 2. Absorbance value of antibody anti Fim-C S. typhimurium in all groups with 100 ng and 300 ng antigen concentration 
Test Bleed 
Experiment  
Group 1 (KP-1) 
Experiment  
Group 2 (KP-2) 
Control  
Group 1(KS-1) 
Control  
Group 2 (KS-2) 
  100 ng 300 ng 100 ng 300 ng 100 ng 300 ng 100 ng 300 ng 
Pre-immune serum 
(test bleed-0) 
0.01550 0.01400 0.01225 0.01275 0.02150 0.02500 0.03150 0.02550 
1st Test Bleed 0.01725 0.01250 0.06875 0.01075 0.02150 0.02300 0.01100 0.02450 
2nd Test Bleed 0.05725 0.13650 0.03250 0.04200 0.01900 0.02250 0.01150 0.01100 
3rd Test Bleed 0.20800 0.27700 0.03450 0.07700 0.00900 0.01300 0.01100 0.01650 
4th Test Bleed 0.21575 0.32575 0.05950 0.14975 0.01150 0.02300 0.00400 0.00500 
        
The increasing of antibody titer of experiment group 1 (immunized by antigen Fim-C S. typhimurium +CA/FIA 
adjuvants (KP-1)) was higher than antibody titer of experiment group 2 (immunized by antigen Fim-C S.
typhimurium + PBS (KP-2)). Those proved that adjuvants can stimulate strong, prolonged responses and protect the 
antigen from releasing faster. As we known adjuvants are nonspecific stimulators immune response. The judicious 
use adjuvants are essential to induce a strong antibody response to soluble antigens11. Perrie et al, 2008 also reported 
the use of adjuvant systems have proven to enhance the immunogenicity of these sub-unit vaccines through 
protection (i.e. preventing degradation of the antigen in vivo) and enhanced targeting of these antigens to 
professional antigen-presenting cells. However, the experiment group 2 (KP-2) also showed antibody response with 
the increasing of antibody titer in each test bleed. That’s means the recombinant protein of Fim-C-S. typhimurium 
have a good immunogenicity, because those protein can induce respon immune without adding the adjuvant. So it’s 
very potential as vaccine candidate. 
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The comparison between experiment group 1 (KP-1) and control group 1 (KS-1) showed significant difference to 
give response immune. FCA/FIA Adjuvant given alone to the control groups did not affect the production of 
antibody. Similar results given by the experiment group 2 (KP-2) and control group 2 (KS-2). The result showed 
that only recombinant protein of Fim-C S. typhimurium antigen can induced the increasing of antibody titer. The 
result also showed that Fim-C S. typhimurium antigen can respond to specific antibody, while PBS as a solvent and 
adjuvant alone does not have immunogenic properties. Compare with other recombinant protein that showed in 
Table 1, mostly the recombinant protein with conjugate, however recombinant protein of Fim. C S. typhimurium 
even without conjugate can produce a good immune respond That showed those protein have good characteristic as 
antigen and vaccine candidate. 
 
 
Fig. 2. The comparison analysis of antibody titer in all groups. The blue line shows the increasing of antibody in experiment group 1 (KP-1). The 
red line shows the increasing of antibody in experiment group 2 (KP-2). The green line shows antibody titer in control group 1 (KS-1). The 
purple line shows antibody titer in control group 2 (KS-2). The comparison was performed in 300 ng antigen concentration and 100 times dilution 
of antibody anti recombinant protein of Fim-C S. typhimurium. 
3.2. Specificity test of anti-Fim-C S. typhimurium antibody 
The results of specificity test of anti Fim-C S. typhimurium antibody by Western Immunoblotting showed 
interaction between Fim-C antigen and anti-Fim-C S. typhimurium antibody. The interaction was made by the 
formation of band with brown color on 31 KDa nitrocellulose membrane, same size as antigen Fim-C S.
typhimurium protein. 
The band with brown color was the results of oxidation reaction with peroxides substances (H2O2), which 
catalyzed by Horse Radish Peroxidase (HRP) enzyme. The Horse Radish Peroxidase (HRP) enzyme changed DAB 
(3,3'-Diaminobenzidine or 3,3',4,4'-Biphenyltetramine) substrate to Quinone Iminium substance which is radical 
properties5. 
Afterward, the Quinone Iminium substance induced the occurrence of polymerization reaction to form polymer 
substance with bigger molecular size and produce precipitate with brown color17. The reaction mechanism to 
produce precipitate in brown color with western Immunoblotting was showed at Fig. 3. The specificity test reported 
in this research was conducted for experiment group and control group. The condition of antigen-antibody 
interaction was respectively as follow (1) 3 μg antigen concentration, (2) 100 times dilution of anti recombinant 
protein of Fim-C S. typhimurium antibody, and (3) 5000 times dilution of secondary antibody anti-mice. 
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Fig. 3. Transformation of DAB Substrate to precipitate with brown color by Western Immunoblotting. DAB (3,3'-Diaminobenzidine or 3,3',4,4'-
Biphenyltetramine) donated electron to HRP which was catalyzed from oxidation reaction of peroxides (H2O2) [ Bio-Rad, Laboratories. Inc, 
2012] 
The Western Immunoblotting showed that the experiment group-1 (KP-1) and experiment group-2 (KP-2) 
produced antibody respond against antigen in nitrocellulose membrane. Meanwhile control group 1 and control 
group 2 did not produce the antibody. The results of testing were shown in Fig. 4. 
 
 
 
Fig. 4. Results of SDS PAGE (blue) and Western Immunoblotting (band with brown color) in all groups. The interaction of antigen-antibody  of 
Fim-C S. typhimurium were identified by the present of band with brown color at column A and column B. Column A: result from SDS PAGE 
and Western Immunoblotting KP-1 group. The column B: result from SDS PAGE and Western Immunoblotting KP-2 group. The column C: 
result from SDS PAGE and Western Immunoblotting KS-1 group. The column D: result from SDS PAGE and Western Immunoblotting KS-2 
group 
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The result showed that recombinant protein of Fim-C S. typhimurium antigens can induce the formation of anti 
recombinant protein of Fim-C specific antibodies, proved by the brown band in membrane nitrocellulose.  
Meanwhile the control group which not gets immunized by Fim-C antigen gave negative results. Based on the 
results we can describe that’s only experiment group 1 and 2 which produce the immune response. As we know 
there are several types of antibodies and antigens, and each antibody is capable of binding only to a specific antigen. 
The specificity of the binding is due to specific chemical constitution of each antibody. The antigenic determinant or 
epitope is recognized by the paratope of antibody, situated at the variable region of the polypeptide chain. The 
variable region in turn has hyper-variable regions which are unique amino acid sequences in each antibody. 
Antigens are bound to antibodies through weak and noncovalent bonds such as electrostatic interactions, hydrogen 
bonds, Van der Waals forces, and hydrophobic interactions18.  
The use of adjuvant systems have proven to enhance the immunogenicity of these sub-unit vaccines through 
protection (i.e. preventing degradation of the antigen in vivo) and enhanced targeting of these antigens to 
professional antigen-presenting cells. Understanding of the immunological implications of the related disease will 
enable validation for the design and development of potential adjuvant systems. Novel adjuvant research involves 
the combination of both pharmaceutical analysis accompanied by detailed immunological investigations, whereby, 
pharmaceutically designed adjuvants are driven by an increased understanding of mechanisms of adjuvant activity, 
largely facilitated by description of highly specific innate immune recognition of components usually associated 
with the presence of invading bacteria or virus. The majority of pharmaceutical based adjuvants currently being 
investigated are particulate based delivery systems, such as liposome formulations11. In this research we used the 
FCA/FIA, in further research we will develop for other safely adjuvant for human.   
 
4. Conclusion  
The recombinant protein of Fim-C-S. typhimurium as antigen can induce the production of anti recombinant 
protein of Fim-C-S. typhimurium antibodies in ddY mice. The serological test with Western Immunoblotting showed 
that recombinant protein of Fim-C S. typhimurium as antigen can interact with specific anti recombinant protein of 
Fim-C S. typhimurium antibodies. The recombinant protein of Fim-C S. typhimurium has good immunogenicity and 
its antibodies are specific. Therefore, it is a significant model in the development of typhoid fever vaccine candidate. 
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